{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-22-003384","form_type":"8-K","ticker":"PBSV","cik":"0001304161","company_name":"Pharma-Bio Serv, Inc.","filed_at":"2022-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.843179+00:00","generated_at":"2026-06-26T21:55:35.049837+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Pharma-Bio Serv Q1 revenue rises to $5.0M; net income flat at $0.3M","bullets":["Revenue of $5.0M, up ~$0.5M YoY; net income unchanged at ~$0.3M.","US and Europe consulting revenue grew to 33% of total, up from 22% YoY.","CEO cites geographic diversification as key to future growth and risk reduction.","No revised guidance or other material operational changes reported."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-22-003384","json":"https://secwatch.observer/filing/0001654954-22-003384.json","markdown":"https://secwatch.observer/filing/0001654954-22-003384.md","text":"https://secwatch.observer/filing/0001654954-22-003384.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1304161/000165495422003384/0001654954-22-003384-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1304161/000165495422003384/pbsv_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T21:55:35.049837+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}